UBS Group Reaffirms Buy Rating for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)‘s stock had its “buy” rating restated by equities researchers at UBS Group in a report issued on Tuesday, The Fly reports.

Other equities research analysts have also issued research reports about the stock. Credit Suisse Group reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Monday, May 10th. Nord/LB raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “buy” rating in a research note on Wednesday, May 12th. Barclays reissued an “overweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, April 28th. Finally, DZ Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, May 11th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold”.

Shares of NYSE FMS opened at $40.29 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $33.84 and a 1 year high of $46.55. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.08 and a quick ratio of 0.80. The company’s 50-day moving average is $41.01. The stock has a market capitalization of $23.60 billion, a PE ratio of 17.99, a P/E/G ratio of 7.08 and a beta of 1.30.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Thursday, May 6th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 6.39% and a return on equity of 10.38%. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $5.29 billion. On average, equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.16 EPS for the current year.

A number of institutional investors have recently modified their holdings of FMS. Quadrant Capital Group LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 26.2% during the first quarter. Quadrant Capital Group LLC now owns 1,339 shares of the company’s stock valued at $49,000 after purchasing an additional 278 shares during the period. Benjamin F. Edwards & Company Inc. lifted its position in Fresenius Medical Care AG & Co. KGaA by 923.8% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,720 shares of the company’s stock valued at $71,000 after purchasing an additional 1,552 shares during the period. JPMorgan Chase & Co. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 441.9% during the first quarter. JPMorgan Chase & Co. now owns 2,162 shares of the company’s stock valued at $80,000 after buying an additional 1,763 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 76.2% during the first quarter. Advisors Asset Management Inc. now owns 3,101 shares of the company’s stock valued at $114,000 after buying an additional 1,341 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in Fresenius Medical Care AG & Co. KGaA by 325.0% during the first quarter. Bank of Montreal Can now owns 3,264 shares of the company’s stock valued at $123,000 after buying an additional 2,496 shares during the last quarter. Institutional investors own 3.32% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also: Options Trading – Understanding Strike Price

The Fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.